Skip to main content
Log in

Adult growth hormone deficiency in patients with fibromyalgia

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Adult growth hormone (GH) deficiency is a welldescribed clinical syndrome with many features reminiscent of fibromyalgia. There is evidence that GH deficiency as defined in terms of a low insulin-like growth factor-1 (IGF-1) level occurs in approximately 30% of patients with fibromyalgia and is probably the cause of some morbidity. It seems most likely that impaired GH secretion in fibromyalgia is related to a physiologic dysregulation of the hypothalamic-pituitary-adrenal axis (HPA) with a resulting increase in hypothalamic somatostatin tone. It is postulated that impaired GH secretion is secondary to chronic physical and psychological stressors. It appears that impaired GH secretion is more common than clinically significant GH deficiency with low IGF-1 levels. The severe GH deficiency that occurs in a subset of patients with fibromyalgia is of clinical relevance because it is a treatable disorder with demonstrated benefits to patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bengtsson A, Henriksson KG, Jorfeldt L, et al.: Primary fibromyalgia: a clinical and laboratory study of 55 patients. Scand J Rheumatol 1986, 15:340–347.

    PubMed  CAS  Google Scholar 

  2. Wolfe F, Smythe HA, Yunus MB, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160–172.

    Article  PubMed  CAS  Google Scholar 

  3. Yunus MB, Masi AT: Juvenile primary fibromyalgia syndrome: a clinical study of thirty-three patients and matched normal controls. Arthritis Rheum 1985, 28:138–145.

    Article  PubMed  CAS  Google Scholar 

  4. Yunus MB, Holt GS, Masi AT, Aldag JC: Fibromyalgia syndrome among the elderly: comparison with younger patients. J Am Geriatr Soc 1988, 36:987–995.

    PubMed  CAS  Google Scholar 

  5. Waxman J, Zatzkis SM: Fibromyalgia and menopause: examination of the relationship. Postgrad Med 1986, 80:165–167, 170–171.

    PubMed  CAS  Google Scholar 

  6. Crofford LJ: Neuroendocrine abnormalities in fibromyalgia and related disorders. Am J Med Sci 1998, 315:359–366. A useful review of the hypothalamic-pituitary-adrenal axis perturbations and hypotheses regarding the associations with pain.

    Article  PubMed  CAS  Google Scholar 

  7. Neeck G: From the fibromyalgia challenge toward a new bio-psycho-social model of rheumatic diseases. Z Rheumatol 1998, 57:A13-A16.

    PubMed  Google Scholar 

  8. Weigent DA, Bradley LA, Blalock JE, Alarcon GS: Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 1998, 315:405–412. A good review of the pathophysiology of aberrant pain perception and its relationships to neuroendocrine dysfunction.

    Article  PubMed  CAS  Google Scholar 

  9. Veldhuis JD, Iranmanesh A: Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996, 19:S221-S224.

    PubMed  CAS  Google Scholar 

  10. Muller EE, Locatelli V, Cocchi D: Neuroendocrine control of growth hormone secretion. Physiol Rev 1999, 79:511–607. An up-to-date review of the neurophysiology of growth hormone secretion.

    PubMed  CAS  Google Scholar 

  11. Hindmarsh PC, Brain CE, Robinson IC, et al.: The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man. Clin Endocrinol (Oxf) 1991, 35:353–360.

    CAS  Google Scholar 

  12. Reid GJ: Textbook of Endocrinology, edn 8. Edited by Wilson JD, Foster MD. Philadelphia: WB Sanders; 1992.

    Google Scholar 

  13. Veldhuis JD, Iranmanesh A, Weltman A: Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine 1997, 7:41–48.

    PubMed  CAS  Google Scholar 

  14. Holl RW, Hartman ML, Veldhuis JD, et al.: Thirty-second sampling of plasma growth hormone in man: correlation with sleep stages. J Clin Endocrinol Metab 1991, 72:854–861.

    PubMed  CAS  Google Scholar 

  15. Davidson JR, Moldofsky H, Lue FA: Growth hormone and cortisol secretion in relation to sleep and wakefulness. J Psychiatry Neurosci 1991, 16:96–102.

    PubMed  CAS  Google Scholar 

  16. Florini JR, Prinz PN, Vitiello MV, Hintz RL: Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol 1985, 40:2–7.

    PubMed  CAS  Google Scholar 

  17. Wallymahmed ME, Foy P, Shaw D, et al.: Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol (Oxf) 1997, 47:439–446.

    Article  CAS  Google Scholar 

  18. Verhelst J, Abs R, Vandeweghe M, et al.: Two years of replacement therapy in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1997, 47:485–494.

    Article  CAS  Google Scholar 

  19. Lieberman SA, Hoffman AR: The somatopause: should growth hormone deficiency in older people be treated? Clin Geriatr Med 1997, 13:671–684.

    PubMed  CAS  Google Scholar 

  20. Cuneo RC, Salomon F, McGauley GA, Sönksen PH: The growth hormone deficiency syndrome in adults. Clin Endocrinol 1992, 37:387–397.

    CAS  Google Scholar 

  21. Wallymahmed ME, Baker GA, Humphris G, et al.: The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1996, 44:403–411.

    Article  CAS  Google Scholar 

  22. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA: Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997, 82:2877–2884.

    Article  PubMed  CAS  Google Scholar 

  23. Rutherford OM, Beshyah SA, Schott J, et al.: Contractile properties of the quadriceps muscle in growth hormone-deficient hypopituitary adults. Clin Sci (Colch) 1995, 88:67–71.

    CAS  Google Scholar 

  24. McGauley GA, Cuneo RC, Salomon F, Sónksen PH: Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm Res 1990, 33:52–54.

    PubMed  Google Scholar 

  25. Salomon F, Cuneo RC, Hesp R, Sonksen PH: The effects of treatment with recombinant human growth hormone XX on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321:1797–1803.

    Article  PubMed  CAS  Google Scholar 

  26. Florini JR: Hormonal control of muscle growth. Muscle Nerve 1987, 10:577–598.

    Article  PubMed  CAS  Google Scholar 

  27. Armstrong RB, Warren GL, Warren JA: Mechanisms of exerciseinduced muscle fibre injury. Sports Med 1991, 12:184–207.

    PubMed  CAS  Google Scholar 

  28. Bennett RM: The contribution of muscle to the generation of fibromyalgia symptomatology. J Musculoskeletal Pain 1996, 4:35–59.

    Article  Google Scholar 

  29. Christ ER, Carroll PV, Russell-Jones DL, Sonksen PH: The consequences of growth hormone deficiency in adulthood, and the effects of growth hormone replacement. Schweiz Med Wochenschr 1997, 127:1440–1449.

    PubMed  CAS  Google Scholar 

  30. Cuneo RC, Judd S, Wallace JD, et al.: The Australian multicenter trial of growth hormone (GH) treatment in GH- deficient adults. J Clin Endocrinol Metab 1998, 83:107–116. An Australian multicenter, randomized, double-blind, placebocontrolled trial of the effects of recombinant human growth hormone (GH) treatment in 166 adults patients (72 women and 91 men) with GH deficiency. GH treatment resulted in prominent increases in serum insulin-like growth factor-1 at the doses used, in some cases to supraphysiologic levels; in modest decreases in total- and low-density lipoprotein cholesterol, together with substantial reductions in total-body and truncal fat mass; in substantial increases in lean tissue mass; and in modest improvements in perceived quality of life.

    Article  PubMed  CAS  Google Scholar 

  31. Giusti M, Meineri I, Malagamba D, et al.: Impact of recombinant human growth hormone treatment on psychological profiles in hypopituitary patients with adult-onset growth hormone deficiency. Eur J Clin Invest 1998, 28:13–19. A study of the effect of growth hormone (GH) administration on the psychological capacity and sense of well-being in 25 patients with adult onset GH deficiency. There were significantly improved psychological profiles, but the quality of life was not significantly improved over the 6-month period of treatment.

    Article  PubMed  CAS  Google Scholar 

  32. Almqvist O, Thoren M, Saaf M, Eriksson O: Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study. Psychoneuroendocrinology 1986, 11:347–352.

    Article  PubMed  CAS  Google Scholar 

  33. Shahi M, Beshyah SA, Hackett D, et al.: Cardiac function and structure in growth hormone deficiency. Br Heart J 1991, 66:58–63.

    Google Scholar 

  34. Cuneo RC, Salomon F, Wiles CM, et al.: Growth hormone treatment in growth hormone-deficient adults, I: effects on muscle mass and strength. J Appl Physiol 1991, 70:688–694.

    PubMed  CAS  Google Scholar 

  35. Aimaretti G, Corneli G, Razzore P, et al.: Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults. J Endocrinol Invest 1998, 21:506–511.

    PubMed  CAS  Google Scholar 

  36. Hoeck HC, Vestergaard P, Jakobsen PE, et al.: Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues. J Clin Endocrinol Metab 2000, 85:1467–1472. A definitive study suggesting that a diagnosis of adult growth hormone (GH) deficiency be based on an abnormally low insulinlike growth factor-1 (IGF-1) level plus one abnormal GH stimulation test, or two abnormal GH stimulation tests in patients with normal IGF-1 levels.

    Article  PubMed  CAS  Google Scholar 

  37. Moldofsky H, Scarisbrick P, England R, Smythe H: Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975, 37:341–351.

    PubMed  CAS  Google Scholar 

  38. Bennett RM: Beyond fibromyalgia: ideas on etiology and treatment. J Rheumatol Suppl 1989, 19:185–191.

    PubMed  CAS  Google Scholar 

  39. Bennett RM, Clark SR, Campbell SM, Burckhardt CS: Low levels of somatomedin C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain. Arthritis Rheum 1992, 35:1113–1116.

    Article  PubMed  CAS  Google Scholar 

  40. Bennett RM, Cook DM, Clark SR, et al.: Hypothalamicpituitary- insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997, 24:1384–1389. A study of 500 patients with fibromyalgia with insulin-like growth factor-1 levels and growth hormone stimulation tests, demonstrating adult growth hormone deficiency in approximately one-third of the patients.

    PubMed  CAS  Google Scholar 

  41. Dinser R, Halama T, Hoffmann A: Stringent endocrinological testing reveals subnormal growth hormone secretion in some patients with fibromyalgia syndrome but rarely severe growth hormone deficiency. J Rheumatol 2000, 27:2482–2488. Supports finding of growth hormone deficiency in approximately one-third of patients with fibromyalgia, but concludes that this is seldom a clinically severe deficiency.

    PubMed  CAS  Google Scholar 

  42. Leal-Cerro A, Povedano J, Astorga R, et al.: The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 1999, 84:3378–3381. A report of 24-hour spontaneous growth hormone (GH) secretion, GH responses to growth hormone-releasing hormone (GHRH), and insulin-like growth factor-1 (IGF-1) and IGF-binding protein (BP)-3 levels in fibromyalgia before and after 4 days of treatment with human GH. It found a marked decrease in spontaneous GH secretion, but normal pituitary responsiveness to exogenously administered GHRH and an increase in IGF-1 and IGFBP-3 levels after GH treatment.

    Article  PubMed  CAS  Google Scholar 

  43. Riedel W, Layka H, Neeck G: Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998, 57:81–87. An excellent review of pituitary axis perturbations in fibromyalgia after injections with corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone, growth hormone-releasing hormone, and luteinizing hormone-releasing hormone. Concludes that elevated activity of hypothalamic CRH neurons in patients with fibromyalgia may play a key role in "resetting" the various endocrine loops and in nociceptive and psychological mechanisms.

    Article  PubMed  CAS  Google Scholar 

  44. Hallegua DS, Wallace DJ, Silverman S, et al.: Prevalence of fibromyalgia in X growth hormone deficiency adults. J Musculoskeletal Pain 2001, 9:35–42.

    Article  Google Scholar 

  45. Bennett RM, Clark SR, Walczyk J: A randomized, doubleblind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227–231. The only controlled study of supplemental growth hormone therapy in fibromyalgia. It found a benefit after approximately 6 months of therapy, and a relapse when therapy was discontinued.

    Article  PubMed  CAS  Google Scholar 

  46. Moorkens G, Wynants H, Abs R: Effect of growth hormone treatment in patients with chronic fatigue syndrome: a preliminary study. Growth Horm IGF Res 1998, 8:131–133.

    Article  PubMed  CAS  Google Scholar 

  47. Chan JM, Stampfer MJ, Giovannucci E, et al.: Plasma insulinlike growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563–566.

    Article  PubMed  CAS  Google Scholar 

  48. Mantzoros CS, Tzonou A, Signorello LB, et al.: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997, 76:1115–1118.

    PubMed  CAS  Google Scholar 

  49. Yee D: The insulin-like growth factors and breast cancer-revisited. Breast Cancer Res Treat 1998, 47:197–199.

    Article  PubMed  CAS  Google Scholar 

  50. Stoll BA: Breast cancer: further metabolic-endocrine risk markers? Br J Cancer 1997, 76:1652–1654.

    PubMed  CAS  Google Scholar 

  51. Sanmarti A, Lucas A, Hawkins F, et al.: Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study): socio-economic impact and health status. Collaborative ODA (Observational GH Deficiency in Adults) Group. Eur J Endocrinol 1999, 141:481–489. A study documenting more cardiovascular risk factors, higher mortality rate, worse quality of life, and higher absolute health costs than the general population in Spain.

    Article  PubMed  CAS  Google Scholar 

  52. Bengtsson BA: The consequences of growth hormone deficiency in adults. Acta Endocrinol 1993, 128:2–5.

    PubMed  Google Scholar 

  53. Paiva ES, Deodhar A, Jones KD, Bennett RM: Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 2002, 46:1344–1350. This study shows that growth hormone (GH) deficiency in fibromyalgia is probably more common than previously reported from the measurements of insulin-like growth factor-1 levels. It provides evidence that perturbed GH secretion in fibromyalgia is probably, in part, a result of increased hypothalamic tone of somatostatin.

    Article  PubMed  CAS  Google Scholar 

  54. Valcavi R, Valente F, Dieguez C, et al.: Evidence against deletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine. J Clin Endocrinol Metab 1993, 77:616–620.

    Article  PubMed  CAS  Google Scholar 

  55. Neeck G, Crofford LJ: Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 2000, 26:989–1002. A comprehensive review of neuroendocrine disorders in fibromyalgia.

    Article  PubMed  CAS  Google Scholar 

  56. Crofford LJ, Engleberg NC, Demitrack MA: Neurohormonal perturbations in fibromyalgia. Baillieres Clin Rheumatol 1996, 10:365–378.

    Article  PubMed  CAS  Google Scholar 

  57. Thorner O: The anterior pituitary. In Textbook of Endocrinology, edn 8. Edited by Wilson JD, Foster DW. Philadelphia: WB Saunders; 1992:221–310.

    Google Scholar 

  58. Devesa J, Lima L, Tresguerres JAF: Neuroendocrine control of growth hormone secretion in humans. Trends Endocrinol Metab 1992, 3:173–181.

    Google Scholar 

  59. Neeck G, Riedel W: Hormonal pertubations in fibromyalgia syndrome. Ann N Y Acad Sci 1999, 876:325–338. Postulates a common primary disturbance in fibromyalgia that is hypothesized to originate within higher levels of the central nervous system. Recent studies of the entire endocrine profile of patients with fibromyalgia after a simultaneous challenge of the hypophysis with corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone, growth hormone-releasing hormone, and luteinizing hormone-releasing hormone support the hypothesis that an elevated activity of CRH neurons determines many symptoms of fibromyalgia and may cause the deviations observed in the other hormonal axes. Hypothalamic CRH neurons may play a key role in "resetting" the various endocrine loops and possibly nociceptive and psychological mechanisms.

    Article  PubMed  CAS  Google Scholar 

  60. Katakami H, Arimura A, Frohman LA: Involvement of hypothalamic somatostatin in the suppression of growth hormone secretion by central corticotropin-releasing factor in conscious male rats. Neuroendocrinology 1985, 41:390–393.

    PubMed  CAS  Google Scholar 

  61. Rivier C, Vale W: Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology 1985, 117:2478–2482.

    Article  PubMed  CAS  Google Scholar 

  62. Hauger RL: Regulation of the stress response by corticotropinreleasing factor receptors. In Neuroendocrinology in Physiology and Medicine. Edited by Conn PMFME. Totowa, NJ: Humana Press; 2000:261–286.

    Google Scholar 

  63. Bonaz B, Rivest S: Effect of a chronic stress on CRF neuronal activity and expression of its type 1 receptor in the rat brain. Am J Physiol 1998, 275:R1438-R1449.

    PubMed  CAS  Google Scholar 

  64. Heim C, Ehlert U, Hanker JP, Hellhammer DH: Abuse-related posttraumatic stress disorder and alterations of the hypothalamic-pituitary-adrenal axis in women with chronic pelvic pain. Psychosom Med 1998, 60:309–318.

    PubMed  CAS  Google Scholar 

  65. Demitrack MA, Dale JK, Straus SE, et al.: Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991, 73:1224–1234.

    PubMed  CAS  Google Scholar 

  66. Heim C, Ehlert U, Hanker JP, Hellhammer DH: Psychological and endocrine correlates of chronic pelvic pain associated with adhesions. J Psychosom Obstet Gynaecol 1999, 20:11–20.

    Article  PubMed  CAS  Google Scholar 

  67. Wittert GA, Livesey JH, Espiner EA, Donald RA: Adaptation of the hypothalamopituitary adrenal axis to chronic exercise stress in humans. Med Sci Sports Exerc 1996, 28:1015–1019.

    PubMed  CAS  Google Scholar 

  68. Clauw DJ, Chrousos GP: Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997, 4:134–153. Hypothesizes that fibromyalgia and chronic fatigue syndrome may result from genetic and environmental factors that interact to cause the development of named syndromes. Various components of the central nervous system may be involved, including the hypothalamic-pituitary axes, pain-processing pathways, and autonomic nervous system.

    PubMed  CAS  Google Scholar 

  69. Dessein PH, Shipton EA, Stanwix AE, Joffe BI: Neuroendocrine deficiency-mediated development and persistence of pain in fibromyalgia: a promising paradigm? Pain 2000, 86:213–215.

    Article  PubMed  CAS  Google Scholar 

  70. Neeck G, Riedel W: Thyroid function in patients with fibromyalgia syndrome. J Rheumatol 1992, 19:1120–1122.

    PubMed  CAS  Google Scholar 

  71. Winfield JB: Pain in fibromyalgia. Rheum Dis Clin North Am 1999, 25:55–79.

    Article  PubMed  CAS  Google Scholar 

  72. Dorn LD, Chrousos GP: The neurobiology of stress: understanding regulation of affect during female biological transitions. Semin Reprod Endocrinol 1997, 15:19–35.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bennett, R.M. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep 4, 306–312 (2002). https://doi.org/10.1007/s11926-002-0039-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-002-0039-4

Keywords

Navigation